![](/-/media/icons/2019/pharma/biomedtracker-icon.png?rev=fc7926a0385c4901b67c1887d9aac276)
King, Palatin terminate bremelanotide deal
Executive Summary
King Pharmaceuticals has licensed exclusive N. American co-promotion rights to Palatin Technologies' PT-141, an inhalable drug candidate in Phase II for sexual dysfunction in men (including erectile dysfunction) and women. King also has exclusive rights to collaborate on the out-licensing of the candidate outside of N. America.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice